Validation of POD24 as a robust early clinical end point of poor ...

Medline ® Abstracts for References 11-21 of 'Treatment of relapsed ...

Validation of POD24 as a robust early clinical end point of poor survival in FL from 5225 patients on 13 clinical trials. ... validating POD24 as a robust ...

Progression of Disease Within 24 Months in Follicular Lymphoma Is ...

... POD24 as an early clinical end point of poor survival in FL. A ... For the BCCA validation cohort, POD24 was observed in 46.7% of low ...

Risk factors for POD24 in patients with previously untreated follicular ...

Validation of POD24 as a robust early clinical end point of poor survival in FL from 5225 patients on 13 clinical trials. Casulo C, Dixon JG ...

Select publications - Research To Practice

Casulo C et al. Validation of POD24 as a robust early clinical endpoint of poor survival in follicular lymphoma: Results from the Follicular ...

Robust prognostic value of histologic transformation in patients with ...

Validation of POD24 as a robust early clinical end point of poor survival in FL from 5225 patients on 13 clinical trials. Blood. 2022;139 ...

Monitoring of Circulating Tumor DNA Predicts Response to ...

Validation of POD24 as a robust early clinical end point of poor survival in. FL from 5225 patients on 13 clinical trials. Blood 2022;139:1684–93. 6. Wagner ...

Connecting clinical trials and population research in follicular ...

Validation of Progression of Disease in 24 months. (POD24) as a Robust Early Clinical Endpoint of Poor. Survival in Follicular Lymphoma: Results From The ...

Early Relapse in First-Line Follicular Lymphoma: A Review of the ...

Validation of POD24 as a robust early clinical endpoint of poor survival in follicular lymphoma: results from the Follicular Lymphoma ...

Clinical Practice Recommendations for Hematopoietic Cell ...

Validation of POD24 as a robust early clinical end point of poor survival in FL from 5225 patients on 13 clinical trials. Blood. 2022; 139:1684-1693. Crossref.

The prognostic index PRIMA-PI combined with Ki67 as a better ...

... patients with POD24 is dissatisfactory, with low Sensitivity. ... end point of poor survival in FL from 5225 patients on 13 clinical trials.

623. Mantle Cell, Follicular, and Other Indolent B Cell Lymphomas ...

299 · Validation of POD24 As a Robust Early Clinical End Point of Poor Survival in Mantle Cell Lymphoma from 1280 Patients on Clinical Trials.

Controversies in the Treatment of Follicular Lymphoma - OUCI

Casulo C, Validation of POD24 as a robust early clinical endpoint of poor survival in follicular lymphoma: results from the follicular lymphoma analysis of ...

Current and future therapies for follicular lymphoma

Validation of POD24 as a robust early clinical end point of poor survival in FL from 5225 patients on 13 clinical trials. Blood. 2022;139(11): ...

Survival by First-line Treatment Type and Timing of Progression ...

(POD24) have a particularly bad prognosis. ... Validation of POD24 as a robust early clinical end point of poor survival in FL from 5225 patients.

Association of early disease progression and very poor survival in ...

Validation of POD24 as a robust early clini- cal endpoint of poor survival in follicular lymphoma: results from the Follicular. Lymphoma Analysis of ...

Epcoritamab monotherapy in patients with relapsed or refractory ...

Validation of POD24 as a robust early clinical end point of poor survival in FL from 5225 patients on 13 clinical trials. Blood. 2022; 139 ...

Management and clinical outcomes of follicular lymphoma across ...

This high proportion of POD24 patients might contribute to the low remission rate of this cohort. However, the 5-year OS rate was 70.4% in ...

Prognostic value of the combination of volume, massiveness and ...

Validation of POD24 as a robust early clinical end point of poor survival in FL from 5225 patients on 13 clinical trials. Blood 139, 1684 ...

Response-Adapted Therapy in Follicular Lymphoma

4. Casulo C, Dixon JG, Le-Rademacher J, et al: Validation of POD24 as a robust early clinical endpoint of poor survival in FL from 5,225 patients on 13 clinical ...

Clinicogenetic risk models predict early progression of follicular ...

Most discriminative classifier for patients without POD24 into high- and low-risk groups. ... end point of poor survival in FL from 5225 patients on 13 clinical ...